Literature DB >> 18800231

Analyses of age, gender and other risk factors of erythropoietin resistance in pediatric and adult dialysis cohorts.

Oluwatoyin Fatai Bamgbola1, Fredrick J Kaskel, Maria Coco.   

Abstract

Previous studies often report lower responses to erythropoietin (EPO) therapy in pediatric patients on chronic dialysis than those of adults. Because of the greater capacity for hematopoiesis in the younger population, these studies may be confounded by poorly identified variables. Thus, we made parallel studies of pediatric and adult cohorts to explore the relationship between age, gender and other risk factors with EPO resistance. Thirty pediatric subjects (aged 8-20 years) and 66 adult subjects (aged 22-85 years) on chronic hemodialysis and EPO were enrolled. After stratification by 50th percentile of EPO response, the best predictive model was identified by backward elimination of the risk factors with the least contribution to the regression. Relationship between age, gender and EPO resistance was examined by analysis of covariance (ANCOVA). The most predictive model of EPO response for the pediatric cohort had, as the major variables, urea clearance x dialysis duration/total body water (Kt/V), urea reduction ratio (URR), intact parathyroid hormone (iPTH), blood loss, normalized protein catabolic rates (nPCR) and indices of malnutrition and inflammation, whereas adults had iron and folate deficiencies as the dominant variables. Although EPO resistance was more common in female subjects than in male subjects, relationship with neither age nor gender was significant. Furthermore, the prescription of a larger (initiating) EPO dose by pediatric physicians compared with adult nephrologists confounded the interaction between age and EPO resistance. In summary EPO resistance in the pediatric dialysis cohort was predicted by nutritional deficits, inflammation, poor dialysis, and hyperparathyroidism, while iron and folate deficits were the major determinants in adults. Although confounded by the pattern of EPO prescription, neither age nor gender was predictive of EPO resistance in the two study groups.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18800231     DOI: 10.1007/s00467-008-0954-3

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  40 in total

1.  Etiology of differences in hematocrit between males and females: sequence-based polymorphisms in erythropoietin and its receptor.

Authors:  S M Zeng; J Yankowitz; J A Widness; R G Strauss
Journal:  J Gend Specif Med       Date:  2001

2.  Quotidian nocturnal hemodialysis improves cytokine profile and enhances erythropoietin responsiveness.

Authors:  Darren Yuen; Robert M A Richardson; Stanley S A Fenton; Margaret E McGrath-Chong; Christopher T Chan
Journal:  ASAIO J       Date:  2005 May-Jun       Impact factor: 2.872

3.  Role of C-reactive protein, reticulocyte haemoglobin content and inflammatory markers in iron and erythropoietin administration in dialysis patients.

Authors:  Mahmoud El-Khatib; Heather J Duncan; K Shashi Kant
Journal:  Nephrology (Carlton)       Date:  2006-10       Impact factor: 2.506

4.  Effect of weekly or successive iron supplementation on erythropoietin doses in patients receiving hemodialysis.

Authors:  A Kato; M Hamada; T Suzuki; T Maruyama; Y Maruyama; A Hishida
Journal:  Nephron       Date:  2001-09       Impact factor: 2.847

5.  rHuEPO treatment improves brain and cognitive function of anemic dialysis patients.

Authors:  J T Marsh; W S Brown; D Wolcott; C R Carr; R Harper; S V Schweitzer; A R Nissenson
Journal:  Kidney Int       Date:  1991-01       Impact factor: 10.612

6.  Epoetin requirements predict mortality in hemodialysis patients.

Authors:  Yi Zhang; Mae Thamer; Kevin Stefanik; James Kaufman; Dennis J Cotter
Journal:  Am J Kidney Dis       Date:  2004-11       Impact factor: 8.860

7.  Identification of poor responders to erythropoietin among children undergoing hemodialysis.

Authors:  W Seeherunvong; L Rubio; C L Abitbol; B Montané; J Strauss; R Diaz; G Zilleruelo
Journal:  J Pediatr       Date:  2001-05       Impact factor: 4.406

8.  Health-related quality of life associated with recombinant human erythropoietin therapy for predialysis chronic renal disease patients.

Authors:  D A Revicki; R E Brown; D H Feeny; D Henry; B P Teehan; M R Rudnick; R L Benz
Journal:  Am J Kidney Dis       Date:  1995-04       Impact factor: 8.860

9.  Estrogen modulates phospholipid acylation in red blood cells: relationship to cell aging.

Authors:  J Le Petit-Thevenin; B Lerique; O Nobili; J Boyer
Journal:  Am J Physiol       Date:  1991-09

Review 10.  Developmental biology of erythropoiesis.

Authors:  J Palis; G B Segel
Journal:  Blood Rev       Date:  1998-06       Impact factor: 8.250

View more
  19 in total

1.  Risk factors for high erythropoiesis stimulating agent resistance index in pre-dialysis chronic kidney disease patients, stages 4 and 5.

Authors:  Ana de Lurdes Agostinho Cabrita; Ana Pinho; Anabela Malho; Elsa Morgado; Marília Faísca; Hermínio Carrasqueira; Ana Paula Silva; Pedro Leão Neves
Journal:  Int Urol Nephrol       Date:  2010-07-17       Impact factor: 2.370

2.  No difference in meeting hemoglobin and albumin targets for dialyzed children with urologic disorders.

Authors:  Rachel M Lestz; Meredith Atkinson; Barbara Fivush; Susan L Furth
Journal:  Pediatr Nephrol       Date:  2011-03-20       Impact factor: 3.714

3.  Association of higher erythropoiesis stimulating agent dose and mortality in children on dialysis.

Authors:  Rachel M Lestz; Barbara A Fivush; Meredith A Atkinson
Journal:  Pediatr Nephrol       Date:  2014-05-03       Impact factor: 3.714

Review 4.  Resistance to erythropoietin-stimulating agents: etiology, evaluation, and therapeutic considerations.

Authors:  Oluwatoyin Bamgbola
Journal:  Pediatr Nephrol       Date:  2011-03-20       Impact factor: 3.714

5.  Risk for anemia in pediatric chronic kidney disease patients: a report of NAPRTCS.

Authors:  Meredith A Atkinson; Karen Martz; Bradley A Warady; Alicia M Neu
Journal:  Pediatr Nephrol       Date:  2010-05-13       Impact factor: 3.714

Review 6.  Hepcidin in anemia of chronic kidney disease: review for the pediatric nephrologist.

Authors:  Meredith A Atkinson; Colin T White
Journal:  Pediatr Nephrol       Date:  2011-03-13       Impact factor: 3.714

Review 7.  Anemia in chronic kidney disease.

Authors:  Meredith A Atkinson; Bradley A Warady
Journal:  Pediatr Nephrol       Date:  2017-04-15       Impact factor: 3.714

8.  Response to erythropoietin in pediatric patients with chronic kidney disease: insights from an in vitro bioassay.

Authors:  Rachel Gavish; Salmas Watad; Nathalie Ben-Califa; Ori Jacob Goldberg; Orly Haskin; Miriam Davidovits; Gili Koren; Yafa Falush; Drorit Neumann; Irit Krause
Journal:  Pediatr Nephrol       Date:  2018-07-20       Impact factor: 3.714

9.  Erythropoietin dosing in children with chronic kidney disease: based on body size or on hemoglobin deficit?

Authors:  Ruediger E Port; Otto Mehls
Journal:  Pediatr Nephrol       Date:  2008-08-12       Impact factor: 3.714

Review 10.  Target hemoglobin trials in chronic kidney disease: design and interpretation issues.

Authors:  Robert N Foley
Journal:  Pediatr Nephrol       Date:  2009-02-17       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.